WCG continues acquisitive streak with biostatistical consultancy buyout

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/IvonneW)
(Image: Getty/IvonneW)

Related tags: WCG, Statistics Collaborative

WCG adds to its portfolio of solutions for clinical trial sponsors by acquiring Statistics Collaborative.

Statistical Collaborative, which is based in Washington, D.C., US, provides biostatistical consulting services to companies developing new drugs and biologics.

In particular, the company offers expertise in trial design, reporting for data monitoring committees, data analysis, and consultation for US Food and Drug Administration presentations. It also works with companies when designing preclinical studies and non-clinical research.

Through the acquisition, WCG will take onboard all of Statistics Collaboration’s staff members and retain the same leadership structure. While the company name will change to simply be prefixed by ‘WCG’.

The financial details of the deal were not disclosed, but WCG will provide its new subsidiary with “access to capital, additional clinical development expertise, and corporate operational support,”​ WCG stated.

For WCG, the strategy continues where 2019 left off – as it consistently adds to its solutions through small-scale acquisitions, year-on-year.

Last year, WCH acquired PharmaSeek​ and Velos’ CTMS internet platform​. A similar pattern unfolded in 2018, when it added ACI Clinical​, and KMR Group and MCC​.

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars